|
|
Line 1: |
Line 1: |
| | | |
| ==Crystal structure of a llama VHH antibody BCD090-M2 against human ErbB3 in space group P1 with cadmium ions== | | ==Crystal structure of a llama VHH antibody BCD090-M2 against human ErbB3 in space group P1 with cadmium ions== |
- | <StructureSection load='6f0d' size='340' side='right' caption='[[6f0d]], [[Resolution|resolution]] 1.90Å' scene=''> | + | <StructureSection load='6f0d' size='340' side='right'caption='[[6f0d]], [[Resolution|resolution]] 1.90Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[6f0d]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Camelus_glama Camelus glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6F0D OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6F0D FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6f0d]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6F0D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6F0D FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CD:CADMIUM+ION'>CD</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9000075Å</td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6ezw|6ezw]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CD:CADMIUM+ION'>CD</scene></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6f0d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6f0d OCA], [http://pdbe.org/6f0d PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6f0d RCSB], [http://www.ebi.ac.uk/pdbsum/6f0d PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6f0d ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6f0d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6f0d OCA], [https://pdbe.org/6f0d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6f0d RCSB], [https://www.ebi.ac.uk/pdbsum/6f0d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6f0d ProSAT]</span></td></tr> |
| </table> | | </table> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
Line 20: |
Line 20: |
| ==See Also== | | ==See Also== |
| *[[Antibody 3D structures|Antibody 3D structures]] | | *[[Antibody 3D structures|Antibody 3D structures]] |
| + | *[[3D structures of non-human antibody|3D structures of non-human antibody]] |
| == References == | | == References == |
| <references/> | | <references/> |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Camelus glama]] | + | [[Category: Lama glama]] |
- | [[Category: Chakchir, O B]] | + | [[Category: Large Structures]] |
- | [[Category: Drozhzhachih, M S]] | + | [[Category: Chakchir OB]] |
- | [[Category: Ekimova, V M]] | + | [[Category: Drozhzhachih MS]] |
- | [[Category: Eliseev, I E]] | + | [[Category: Ekimova VM]] |
- | [[Category: Evstratyeva, A V]] | + | [[Category: Eliseev IE]] |
- | [[Category: Krendeleva, E A]] | + | [[Category: Evstratyeva AV]] |
- | [[Category: Lomovskaya, M I]] | + | [[Category: Krendeleva EA]] |
- | [[Category: Moiseenko, F V]] | + | [[Category: Lomovskaya MI]] |
- | [[Category: Nemankin, T A]] | + | [[Category: Moiseenko FV]] |
- | [[Category: Svirina, A A]] | + | [[Category: Nemankin TA]] |
- | [[Category: Ulitin, A B]] | + | [[Category: Svirina AA]] |
- | [[Category: Vladimirova, A K]] | + | [[Category: Ulitin AB]] |
- | [[Category: Vysochinskaya, V V]] | + | [[Category: Vladimirova AK]] |
- | [[Category: Yakovlev, P A]] | + | [[Category: Vysochinskaya VV]] |
- | [[Category: Yudenko, A N]] | + | [[Category: Yakovlev PA]] |
- | [[Category: Erbb3]]
| + | [[Category: Yudenko AN]] |
- | [[Category: Her3]]
| + | |
- | [[Category: Immune system]]
| + | |
- | [[Category: Llama antibody]]
| + | |
- | [[Category: Nanobody]]
| + | |
- | [[Category: Receptor tyrosine kinase]]
| + | |
- | [[Category: Single-domain antibody]]
| + | |
- | [[Category: Vhh]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Background: The ability of ErbB3 receptor to functionally complement ErbB1-2 and induce tumor resistance to their inhibitors makes it a unique target in cancer therapy by monoclonal antibodies. Here we report the expression, purification and structural analysis of a new anti-ErbB3 single-chain antibody. Methods: The VHH fragment of the antibody was expressed in E. coli SHuffle cells as a SUMO fusion, cleaved by TEV protease and purified to homogeneity. Binding to the extracellular domain of ErbB3 was studied by surface plasmon resonance. For structural studies, the antibody was crystallized by hanging-drop vapor diffusion in two different forms. Results: We developed a robust and efficient system for recombinant expression of single-domain antibodies. The purified antibody was functional and bound ErbB3 with K D =15+/-1 nM. The crystal structures of the VHH antibody in space groups C2 and P1 were solved by molecular replacement at 1.6 and 1.9 A resolution. The high-quality electron density maps allowed us to build precise atomic models of the antibody and the putative paratope. Surprisingly, the CDR H2 existed in multiple distant conformations in different crystal forms, while the more complex CDR H3 had a low structural variability. The structures were deposited under PDB entry codes 6EZW and 6F0D. Conclusions: Our results may facilitate further mechanistic studies of ErbB3 inhibition by single-chain antibodies. Besides, the solved structures will contribute to datasets required to develop new computational methods for antibody modeling and design.
Crystal structures of a llama VHH antibody BCD090-M2 targeting human ErbB3 receptor.,Eliseev IE, Yudenko AN, Vysochinskaya VV, Svirina AA, Evstratyeva AV, Drozhzhachih MS, Krendeleva EA, Vladimirova AK, Nemankin TA, Ekimova VM, Ulitin AB, Lomovskaya MI, Yakovlev PA, Bukatin AS, Knyazev NA, Moiseenko FV, Chakchir OB F1000Res. 2018 Jan 16;7:57. doi: 10.12688/f1000research.13612.2. eCollection, 2018. PMID:30430004[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Eliseev IE, Yudenko AN, Vysochinskaya VV, Svirina AA, Evstratyeva AV, Drozhzhachih MS, Krendeleva EA, Vladimirova AK, Nemankin TA, Ekimova VM, Ulitin AB, Lomovskaya MI, Yakovlev PA, Bukatin AS, Knyazev NA, Moiseenko FV, Chakchir OB. Crystal structures of a llama VHH antibody BCD090-M2 targeting human ErbB3 receptor. F1000Res. 2018 Jan 16;7:57. doi: 10.12688/f1000research.13612.2. eCollection, 2018. PMID:30430004 doi:http://dx.doi.org/10.12688/f1000research.13612.2
|